Heart disease is more common in people over 65, but treatments are better than ever. That can...
Author - David Miller
Ladrones de Ozempic: la nueva ola delictiva en Brasil
En un país obsesionado con la imagen corporal, bandas delictivas roban medicamentos para perder...
Savings and Sustainability Sought by Pharma Partners
With 2025 now in full swing, this article presents a review of the latest developments in...
Decades of LDT Tension Leads to an Epic Three-Hour Oral Argument
By Allyson B. Mullen & Jeffrey N. Gibbs — The multi-decade battle over FDA’s power to regulate...
FDA Grants Priority Review to Merck’s Keytruda for Resectable...
Keytruda demonstrated a statistically significant and clinically meaningful improvement in...
Opinion: What academic research could learn from college...
Since the end of World War II, the business plan of American universities has included two key...
FDA Approves Prolacta Bioscience’s Surgifort for Infants...
Surgifort is the first FDA-approved human milk-based fortifier specifically designed for term...
FDA Approves First Treatment for Rare Lipid Storage Disease...
Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that...
On a Mission to Heal Gila Monsters
After years in Big Pharma, a chemist pivoted to help save the species that made Ozempic possible.
Warning Letters: An Untapped Source for Understanding When...
By Steven J. Gonzalez & Allyson B. Mullen — As the device industry is well aware, one of the...